Combination therapies using vitamin B12 and therapeutic agents for treatment of viral, proliferative and inflammatory diseases
AssigneeTransition Therapeutics Inc.
InventorsTony Cruz, Aleksandra Pastrak
Life of this patent
Estimating the term…
Abstract
Pharmaceutical compositions for treating viral, proliferative and inflammatory diseases are disclosed comprising an amount of pharmaceutically acceptable vitamin B12 compounds in combination with anti-viral, anti-proliferative and anti-inflammatory compounds. Vitamin B12 compounds are administered separately, simultaneously or in combination with anti-viral, anti-proliferative and/or anti-inflammatory compounds to provide an enhanced therapeutic effect for treating viral, proliferative and inflammatory diseases.
Claims24
A pharmaceutical composition for the treatment of a disease selected from the group consisting of:
- viral diseases;
- proliferative diseases;
- inflammatory diseases;
- proliferative and inflammatory diseases;
- proliferative and viral diseases;
- viral and inflammatory diseases;
- and proliferative, viral and inflammatory diseases;
- comprising:
- (i) At least one vitamin B12 compound;
- and
- (ii) At least one second compound selected from the group consisting of:
- an anti-viral compound;
- an anti-proliferative compound;
- and an anti-inflammatory compound.
A pharmaceutical composition for the treatment of proliferative diseases comprising:
- (i) At least one vitamin B12 compound;
- and
- (ii) At least one anti-proliferative compound.
A pharmaceutical composition for the treatment of viral diseases comprising:
- (i) At least one vitamin B12 compound;
- and
- (ii) At least one anti-viral compound.
A pharmaceutical composition for the treatment of inflammatory diseases comprising:
- (i) At least one vitamin B12 compound;
- and
- (ii) At least one anti-inflammatory compound.
A pharmaceutical composition for the treatment of a virus selected from the group consisting of Hepatitis B, hepatitis C, herpes simplex virus type 2 and vesticular stomatitis virus comprising:
- (i) At least one vitamin B12 compound;
- and
- (ii) At least one interferon compound.
A pharmaceutical composition for the treatment of cancer comprising:
- (i) At least one vitamin B12 compound;
- and
- (ii) At least anti-proliferative compound.
A pharmaceutical composition for the treatment of astrocytoma and glioma comprising:
- (i) At least one vitamin B12 compound;
- and
- (ii) At least anti-proliferative compound.
A pharmaceutical composition for the treatment of hepatitis C comprising:
- (i) At least one vitamin B12 compound;
- and
- (ii) At least one interferon compound
A pharmaceutical composition for the treatment of cancer comprising:
- (i) At least one vitamin B12 compound;
- and
- (ii) Paclitaxel.
A pharmaceutical composition for the treatment of astrocytoma and glioma comprising:
- (i) At least one vitamin B12 compound;
- and
- (ii) Paclitaxel.
A pharmaceutical composition for the treatment of astrocytoma and glioma comprising:
- (i) At least one vitamin B12 compound;
- and
- (ii) At least one interferon compound.
A pharmaceutical composition for the treatment of multiple sclerosis comprising:
- (i) Vitamin B12;
- and
- (ii) A peptide selected from the group consisting of P16, S-3, S-7, P-32, V-2 and V-3.
A pharmaceutical composition for the treatment of Hepatitis B comprising:
- (i) Vitamin B12;
- and
- (ii) Interferon
A method of treating a disease selected from the group consisting of viral, proliferative and inflammatory diseases comprising the steps of administering to a patient, either together, or separately:
- (a) At least one Vitamin B12 compound;
- and
- (b) At least one compound selected from the group consisting of:
- an anti-viral compound, an anti-proliferative compound, and an anti-inflammatory compound.
Dependencies are inferred from the claim text.